BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ge M, Molina J, Ducasa GM, Mallela SK, Varona Santos J, Mitrofanova A, Kim JJ, Liu X, Sloan A, Mendez AJ, Banerjee S, Liu S, Szeto HH, Shin MK, Hoek M, Kopp JB, Fontanesi F, Merscher S, Fornoni A. APOL1 risk variants affect podocyte lipid homeostasis and energy production in focal segmental glomerulosclerosis. Hum Mol Genet 2021;30:182-97. [PMID: 33517446 DOI: 10.1093/hmg/ddab022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu T, Yang L, Mao H, Ma F, Wang Y, Li S, Li P, Zhan Y. Sirtuins as novel pharmacological targets in podocyte injury and related glomerular diseases. Biomed Pharmacother 2022;155:113620. [PMID: 36122519 DOI: 10.1016/j.biopha.2022.113620] [Reference Citation Analysis]
2 Liu T, Jin Q, Ren F, Yang L, Mao H, Ma F, Wang Y, Li P, Zhan Y. Potential therapeutic effects of natural compounds targeting autophagy to alleviate podocyte injury in glomerular diseases. Biomed Pharmacother 2022;155:113670. [PMID: 36116248 DOI: 10.1016/j.biopha.2022.113670] [Reference Citation Analysis]
3 Pressly JD, Gurumani MZ, Varona Santos JT, Fornoni A, Merscher S, Al-Ali H. Adaptive and maladaptive roles of lipid droplets in health and disease. Am J Physiol Cell Physiol 2022. [PMID: 35108119 DOI: 10.1152/ajpcell.00239.2021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Muehlig AK, Gies S, Huber TB, Braun F. Collapsing Focal Segmental Glomerulosclerosis in Viral Infections. Front Immunol 2021;12:800074. [PMID: 35095882 DOI: 10.3389/fimmu.2021.800074] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
5 Tzukerman M, Shamai Y, Abramovich I, Gottlieb E, Selig S, Skorecki K. Comparative Analysis of the APOL1 Variants in the Genetic Landscape of Renal Carcinoma Cells. Cancers (Basel) 2022;14:733. [PMID: 35159001 DOI: 10.3390/cancers14030733] [Reference Citation Analysis]
6 Audzeyenka I, Bierżyńska A, Lay AC. Podocyte bioenergetics in the development of diabetic nephropathy: the role of mitochondria. Endocrinology 2021:bqab234. [PMID: 34791124 DOI: 10.1210/endocr/bqab234] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
7 Yoshida T, Latt KZ, Heymann J, Kopp JB. Lessons From APOL1 Animal Models. Front Med (Lausanne) 2021;8:762901. [PMID: 34765626 DOI: 10.3389/fmed.2021.762901] [Reference Citation Analysis]
8 Ge M, Merscher S, Fornoni A. Use of Lipid-Modifying Agents for the Treatment of Glomerular Diseases. J Pers Med 2021;11:820. [PMID: 34442464 DOI: 10.3390/jpm11080820] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Ekulu PM, Adebayo OC, Decuypere JP, Bellucci L, Elmonem MA, Nkoy AB, Mekahli D, Bussolati B, van den Heuvel LP, Arcolino FO, Levtchenko EN. Novel Human Podocyte Cell Model Carrying G2/G2 APOL1 High-Risk Genotype. Cells 2021;10:1914. [PMID: 34440683 DOI: 10.3390/cells10081914] [Cited by in F6Publishing: 1] [Reference Citation Analysis]